Registry for Advanced Sarcodiosis

Sarcoidosis Clinical Trial

— REAS  

Official title:

Registry for Advanced Sarcoidosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03769987
• Other study ID #: REAS
• Status: Recruiting
• Start date: January 1, 2017
• Est. completion date: June 30, 2020

Study information

• Verified date: December 2018
• Source: University of Cincinnati
• Contact: Robert Baughman
• Phone: 513-584-5225
• Email: bob.baughman[@]uc.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Registry with evaluation and genetic information of patients with advanced sarcoidosis and matched sarcoidosis

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 800
• Est. completion date: June 30, 2020
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years to 100 Years

Eligibility

Inclusion criteria

• Patients with diagnosis of sarcoidosis based on ATS/WASOG criteria 22

• Age = 18 years.

• Life expectancy of at least 2 years.

• Pulmonary function tests (spirometry) within one month of entry or willing to under pulmonary function testing on the day of study enrollment

• Sarcoidosis as characterized as either advanced or non-advanced (see protocol for definition of advanced disease)

• Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.

Exclusion criteria

• Subjects with a medical disorder, condition, or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator

• Inability to comply with the protocol and/or not willing or not available for follow-up assessments.

• Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.

Related Conditions & MeSH terms

• Sarcoidosis

Intervention

Other:
• observation
observe patients every 6 months

Locations

Country	Name	City	State
United States	University of Cincinnati	Cincinnati	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
University of Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Death	Determine how many people die during follow up	2 years